Geovax Labs에 대한 매도 수량은 투자자에게 Geovax Labs의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Geovax Labs (NASDAQ:GOVX) 주식, 공매도 수량 보고

GEOVAX LABS INC

Geovax Labs

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Nvidia,Logo,On,Mobile,Phone,Screen,Company,Shares,Rise,Or

Exclusives

Trading Ideas

AAPL

AMZN

APLD

CNEY

GLMD

GOVX

IMRX

INTC

LUMN

LUNR

NDRA

NVDA

PLTR

SMCI

SMMT

TNON

TSLA

WHLR

매일 거래일마다 벤징가 프로(Benzinga Pro)에서 수백 개의 헤드라인과 보도자료가 올라온다. 이는 트레이더들이 전체 시장 및 개별 종목에 대한 최신 뉴스를 확인할 수 있는 소스이다. 2024년 9월에 Benzinga Pro에서 가장 많이 검색된 주식들을 살펴보겠다. 현재 가격과 연초 대비 성과는 9월 30일 기준이며 배당금은 포함되지 않았다.

독점: 9월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 - 테슬라, 엔비디아, 애플은 어디에?

wall-street-ai17

Broad U.S. Equity ETFs

Tech

ETFs

APDN

ASTS

CING

CRWD

INDO

SERV

VRAX

ZAPP

매일의 거래일에는 트레이더들이 전체 시장과 개별 종목들에 대한 최신 뉴스를 볼 수 있는 소스인 Benzinga Pro에 수백 개의 헤드라인과 보도 자료가 제공된다. 2024년 8월 한 달 동안 Benzinga Pro에서 가장 많이 검색된 주식을 살펴보자. 현재 가격과 연간 실적은 8월 30일을 기준으로 하며 배당금은 포함되지 않았다. 4월 검색결과는 추적되지 않았다.

단독: 2024년 8월 벤징가 프로에서 가장 검색량이 많았던 상위 20개 티커는?

Mpox As A Planned Pandemic

Biotech

News

Health Care

After-Hours Center

Movers

지오백스 랩스(NASDAQ:GOVX)의 주가는 수요일 뉴욕 시장 마감을 앞두고 급등했고, 미시간주 웨인(Wayne) 카운티에서 2022년 이후 첫 번째 엠폭스(mpox, 원숭이두창) 사례가 확인됐다는 보도가 나온 후 시간외 거래에서 계속해서 반등했다.

지오백스의 주식, 수요일 시장 마감 직전부터 시간외 거래까지 급등 지속: 무슨 일이?

Geovax Labs Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group cut Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) price target from $10 to $9. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Kohl&#8217;s shares closed at $7.21 on Thursday. <a href="https://www.benzinga.com/quote/KSS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised the price target for Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from $400 to $460. Needham analyst Ryan MacDonald maintained a Buy rating. Duolingo shares closed at $400.00 on Thursday. <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital raised Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) price target from $300 to $325. Chardan Capital analyst Keay Nakae maintained a Buy rating. Alnylam Pharmaceuticals shares closed at $255.13 on Thursday. <a href="https://www.benzinga.com/quote/ALNY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity slashed the price target for Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Block shares closed at $58.48 on Thursday. <a href="https://www.benzinga.com/quote/XYZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>D. Boral Capital cut the price target for GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) from $14 to $9. D. Boral Capital analyst Jason Kolbert maintained a Buy rating. GeoVax Labs shares closed at $0.9893 on Thursday. <a href="https://www.benzinga.com/quote/GOVX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson raised Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) price target from $230 to $250. DA Davidson analyst Gil Luria maintained a Buy rating. Apple shares settled at $213.32 on Thursday. <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies cut Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) price target from $52 to $10. Jefferies analyst Akash Tewari downgraded the stock from Buy to Hold. Arvinas shares closed at $7.23 on Thursday. <a href="https://www.benzinga.com/quote/ARVN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut Clear Secure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOU#NYSE">YOU</a>) price target from $42 to $32. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. Clear Secure shares closed at $24.40 on Thursday.  <a href="https://www.benzinga.com/quote/YOU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham lowered the price target for Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) from $52 to $40. Needham analyst Scott Berg maintained a Buy rating. Five9 shares settled at $25.08 on Thursday. <a href="https://www.benzinga.com/quote/FIVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Canaccord Genuity increased Strategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) price target from $409 to $464. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Strategy shares closed at $381.60 on Thursday. <a href="https://www.benzinga.com/quote/MSTR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAPL stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="606" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png" alt="" class="wp-image-898959" style="width:588px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-1024x606.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-300x177.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23-768x454.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/02075526/image-23.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45133450/jim-cramer-this-consumer-cyclical-stock-is-a-one-trick-pony">Jim Cramer: This Consumer Cyclical Stock Is A &#8216;One-Trick Pony&#8217;</a> </li>
</ul>
Photo via Shutterstock

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

ALNY

ARVN

DUOL

FIVN

MSTR

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and lowers the price target from $14 to $9.

D. Boral Capital Maintains Buy on Geovax Labs, Lowers Price Target to $9

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $8 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Geovax Labs, Maintains $8 Price Target

<h3>Gainers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) stock increased by 145.5% to $2.53 during Tuesday's regular session. The market value of their outstanding shares is at $43.5 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock moved upwards by 36.64% to $1.79. The market value of their outstanding shares is at $55.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock moved upwards by 32.57% to $3.98. The company's market cap stands at $7.6 million. </li>
<li>Phio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) shares increased by 29.47% to $2.85. The market value of their outstanding shares is at $13.6 million. </li>
<li>Verve Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERV#NASDAQ">VERV</a>) shares increased by 24.51% to $5.13. The company's market cap stands at $455.5 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock rose 21.12% to $0.99. The company's market cap stands at $7.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock declined by 55.9% to $0.14 during Tuesday's regular session. The market value of their outstanding shares is at $5.7 million. The company's, Q4 earnings came out today. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock declined by 37.78% to $1.15. The company's market cap stands at $9.9 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSPR#NASDAQ">MSPR</a>) shares decreased by 22.27% to $2.2. The market value of their outstanding shares is at $4.6 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) shares declined by 22.26% to $0.37. The market value of their outstanding shares is at $4.2 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 21.73% to $0.84. The company's market cap stands at $7.9 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock fell 19.3% to $0.03. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DWTX

MSPR

MTVA

MURA

PHIO

SKYE

SPRB

STSS

VERV

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones  index gaining around 50 points on Tuesday.
The Dow traded up 0.17% to 40,592.77 while the NASDAQ gained 0.39% to 16,896.58. The S&amp;P 500 also rose, gaining, 0.35% to 5,424.63.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44811469/how-to-earn-500-a-month-from-abbott-laboratories-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 1.2% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
Top Headline
Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) posted better-than-expected earnings for its first quarter.
Citigroup reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.84 per share. The company reported quarterly sales of $21.60 billion which beat the analyst consensus estimate of $21.29 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares shot up 146% to $2.5299 after the company announced plans to explore strategic alternatives and discontinue clinical development of nemvaleukin.</li>
<li>Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>)got a boost, surging 51% to $1.98 after the company reported weight loss results from its Nimacimab and Tirzepatide preclinical obesity model.</li>
<li>Rezolve AI PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares were also up, gaining 24% to $1.4160 as the company announced a $9.8 million yearly contract with Liverpool Mexico.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 59% to $0.1299 as the company announced new corporate strategy and acquisition of Tralesinidase Alfa for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).</li>
<li>Shares of GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) were down 31% to $0.7439 after multiple firms cut their respective price targets on the stock.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) was down, falling 27% to $3.9207 following weak quarterly revenue.</li>
</ul>
Commodities In commodity news, oil traded down 0.8% to $61.02 while gold traded up 0.4% at $3,237.90.
Silver traded up 0.1% to $32.180 on Tuesday, while copper fell 0.5% to $4.6015.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 1.69%, Germany's DAX 40 gained 1.51% and France's CAC 40 climbed 0.96%. Spain's IBEX 35 Index surged 2.09%, while London's FTSE 100 rose 1.45%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.84%, China's Shanghai Composite gaining 0.15%, Hong Kong's Gang Seng index rising 0.23% and India's BSE Sensex gaining 2.1%.
Economics
<ul>
<li>The NY Empire State Manufacturing Index climbed to -8.1 in April compared to -20 in the previous month.</li>
<li>U.S. export prices came in unchanged in March compared to a revised 0.5% gain in February.</li>
<li>U.S. import prices fell by 0.1% in March 2025 compared to a revised 0.2% gain in February.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a></li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

RZLV

Crude Oil Moves Lower; Citigroup Posts Upbeat Results

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.41% to 40,689.26 while the NASDAQ gained 0.60% to 16,932.04. The S&amp;P 500 also rose, gaining, 0.55% to 5,435.97.
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/04/44811469/how-to-earn-500-a-month-from-abbott-laboratories-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 1.3% on Tuesday.
In trading on Tuesday, health care shares fell by 0.3%.
Top Headline
Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) posted better-than-expected earnings for its first quarter.
Bank of America reported quarterly earnings of 90 cents per share which beat the analyst consensus estimate of 81 cents per share. The company reported quarterly sales of $27.40 billion which beat the analyst consensus estimate of $26.99 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares shot up 139% to $2.46 after the company announced plans to explore strategic alternatives and discontinue clinical development of nemvaleukin.</li>
<li>Shares of Skye Bioscience, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>)got a boost, surging 119% to $2.8699 after the company reported weight loss results from its Nimacimab and Tirzepatide preclinical obesity model.</li>
<li>Synergy CHC Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) shares were also up, gaining 71% to $3.0550.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Spruce Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) shares dropped 58% to $0.1327 as the company announced new corporate strategy and acquisition of Tralesinidase Alfa for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).</li>
<li>Shares of GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) were down 27% to $0.7768 after multiple firms cut their respective price targets on the stock.</li>
<li>Webull Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) was down, falling 19% to $50.71.</li>
</ul>
Commodities In commodity news, oil traded up 0.2% to $61.64 while gold traded up 0.1% at $3,229.40.
Silver traded up 0.2% to $32.215 on Tuesday, while copper fell 0.5% to $4.6015.
Euro zone
European shares were higher today. The eurozone's STOXX 600 jumped 1.5%, Germany's DAX 40 gained 1.4% and France's CAC 40 climbed 0.7%. Spain's IBEX 35 Index surged 2%, while London's FTSE 100 rose 1.2%.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.84%, China's Shanghai Composite gaining 0.15%, Hong Kong's Gang Seng index rising 0.23% and India's BSE Sensex gaining 2.1%.
Economics
<ul>
<li>The NY Empire State Manufacturing Index climbed to -8.1 in April compared to -20 in the previous month.</li>
<li>U.S. export prices came in unchanged in March compared to a revised 0.5% gain in February.</li>
<li>U.S. import prices fell by 0.1% in March 2025 compared to a revised 0.2% gain in February.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a></li>
</ul>
Photo via Shutterstock

Equities

BULL

SNYR

Nasdaq Surges 100 Points; Bank of America Earnings Top Views

WIIM

GeoVax Labs shares are trading lower after multiple firms cut their respective price targets on the stock.

<h3>Gainers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares increased by 31.1% to $1.35 during Tuesday's pre-market session. The company's market cap stands at $23.2 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock rose 20.36% to $2.36. The company's market cap stands at $3.3 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares rose 17.36% to $0.58. The market value of their outstanding shares is at $16.2 million. </li>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) stock rose 15.61% to $1.15. The company's market cap stands at $55.3 million. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) shares increased by 14.13% to $2.1. The company's market cap stands at $18.1 million. </li>
<li>Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) shares increased by 12.73% to $5.03. The company's market cap stands at $52.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares fell 54.7% to $0.91 during Tuesday's pre-market session. The market value of their outstanding shares is at $37.1 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.92% to $0.75. The company's market cap stands at $7.0 million. </li>
<li>Spruce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRB#NASDAQ">SPRB</a>) stock fell 23.35% to $0.24. The company's market cap stands at $9.9 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock fell 21.34% to $1.4. The market value of their outstanding shares is at $18.6 million. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) shares decreased by 21.03% to $0.16. The market value of their outstanding shares is at $4.8 million. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock decreased by 20.42% to $2.3. The company's market cap stands at $152.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DTIL

ELUT

ENSC

GUTS

ONMD

SOPH

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and lowers the price target from $18 to $14.

D. Boral Capital Maintains Buy on Geovax Labs, Lowers Price Target to $14

U.S. stock futures were volatile on Tuesday following a two-day advance. Futures of major benchmark indices were mixed in premarket.
Donald Trump hinted at helping the car companies while talking to reporters in his Oval Office on Monday. He explained that automakers require a transition period to shift production from Canada, Mexico, and elsewhere.
&#8220;And they need a little bit of time because they're going to make them here, but they need a little bit of time. So I'm talking about things like that,&#8221; he said.
Stocks advanced for two consecutive days after he exempted smartphones, computers, and semiconductors from the reciprocal tariffs on Friday. However, he hinted that he may look at levying duties on the chips imported into the U.S. on Sunday in a Truth Social post.
The 10-year Treasury bond yielded 4.38% and the two-year bond was at 3.86%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing an 82.7% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.03%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.08%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.25%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.12%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Tuesday. The SPY was up 0.013% to $539.19, while the QQQ advanced 0.22% to $458.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Led by technology stocks, U.S. equities closed higher on Monday. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares surged 2.2%, and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELLL#NYSE">DELLL</a>) gained approximately 4%, contributing to a roughly 1% rise in the Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>).
Financials presented a mixed picture, with Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) reporting stronger-than-anticipated first-quarter earnings, while M&amp;T Bank Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) posted weaker-than-expected results.
Real estate, utilities, and consumer staples sectors recorded the most significant gains on Monday. Conversely, consumer discretionary stocks trended lower.
As of Monday&#8217;s close, the Dow Jones index was 10.1% lower than its 52-week high of 45,073.63 points. The S&amp;P 500 index was 12.06% lower than its previous high of 6,147.43 points, and the Nasdaq 100 index was down 15.42% from its last record high of 22,222.61 points.
The Dow Jones index climbed 312 points or 0.78% to 40,524.79, whereas the S&amp;P 500 index advanced 0.79% to 5,405.97. Nasdaq Composite rose to end 0.64% higher at 16,831.48, and the small-cap gauge, Russell 2000, jumped 1.11% to 1,880.88.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.64%</td>
<td>16,831.48</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.79%</td>
<td>5,405.97</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.78%</td>
<td>40,524.79</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.11%</td>
<td>1,880.88</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ark Invest CEO Cathie Wood said that she sees a &#8220;light at the end of the tunnel,&#8221; despite the ongoing<a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump"> tariff turmoil</a>. According to Wood, tariffs could be the catalyst to end a three-year "rolling recession."
She said that Trump&#8217;s decision to bring Treasury Secretary Scott Bessent into the process indicates a move to reduce both tariffs and non-tariff trade obstacles. She contends this shift wouldn&#8217;t have occurred without the initial &#8220;shock therapy&#8221; of aggressive trade measures.
The slowdown caused by the tariff introduction will give the administration and the Federal Reserve "more degrees of freedom to stimulate than most investors have been expecting,&#8221; she said.
This will create a "clarion call" for tax cuts, deregulation, and lower interest rates, ultimately paving the way for economic recovery, Wood added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While the last two weeks of tariff turmoil have been challenging for financial markets, we see light at the end of the tunnel! <a href="https://t.co/cexMNdtbLp">https://t.co/cexMNdtbLp</a>
&mdash; Cathie Wood (@CathieDWood) <a href="https://twitter.com/CathieDWood/status/1911969728337186973?ref_src=twsrc%5Etfw">April 15, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The analysts at BlackRock extended their tactical horizon back to six to 12 months and resumed their positive view on U.S., while still expecting the &#8220;ongoing risk asset volatility and potentially sharp reversals.&#8221;
Spiking yields in long-term U.S. Treasuries seemed to be a factor in the change in tariff tactics, the weekly note stated.
&#8220;We stay underweight long-term Treasuries, our highest conviction view: tariffs are likely to add to already sticky inflation, and congressional budget plans last week reinforce the outlook for persistent budget deficits. We favor gold instead as a portfolio diversifier.&#8221;
According to BlackRock, the broad-based equity selloff has created opportunities to tap into certain sectors, and &#8220;selectivity is key.&#8221;
&#8220;We still like U.S. technology benefitting from the AI buildout and adoption. We also favor global banks. That includes U.S. banks given the scope for deregulation even with some potential economic pain.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Tuesday:
<ul>
<li>March&#8217;s import price index data and April&#8217;s Empire State manufacturing survey data will be released by 8:30 a.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) rose 1.09% in premarket on Tuesday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.85 per share on revenue of $21.29 billion.</li>
</ul>
<ul>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) was down 0.29% as Wall Street expects it to report earnings of $2.60 per share on revenue of $21.58 billion before the opening bell.</li>
</ul>
<ul>
<li>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) was up 0.76% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 82 cents per share on revenue of $26.99 billion.</li>
</ul>
<ul>
<li>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) declined 0.12% as Wall Street expects it to report earnings of 76 cents per share on revenue of $13.26 billion after the closing bell.</li>
</ul>
<ul>
<li>Telefonaktiebolaget LM Ericsson ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) jumped 6.17% after reporting that its first-quarter adjusted operating earnings, excluding restructuring charges, jumped 44% year-over-year to 6.2 billion Swedish crowns ($636 million).</li>
</ul>
<ul>
<li>Lowe&#8217;s Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) advanced by 0.58% as it announced the purchase of an interior design company, Artisan Design Group, for $1.3 billion.</li>
</ul>
<ul>
<li>ARB IOT Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) surged 33.83% after securing a $53 million deal to provide AI servers to Whizzl Group, boosting its AI infrastructure presence and strengthening its position in the AI and data center markets.</li>
</ul>
<ul>
<li>Geovax Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) slumped 34.57% after it was directed by the Biomedical Advanced Research and Development Authority on April 11 to halt its Phase 2b COVID-19 vaccine trial.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.29% to hover around $61.35 per barrel.
Gold Spot US Dollar advanced 0.46% to hover around $3,223.97 per ounce. Its fresh record high stood at $3,245.84 per ounce. The U.S. Dollar Index spot was lower by 0.06% at the 99.585 level.
Asian markets rose on Tuesday, including India's S&amp;P BSE Sensex, China&#8217;s CSI 300, Hong Kong's Hang Seng, Japan's Nikkei 225, Australia's ASX 200, and South Korea's Kospi index. European markets were also higher in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44807265/cathie-wood-says-shock-therapy-from-trumps-trade-moves-may-end-prolonged-economic-slump">Cathie Wood Says &#8216;Shock Therapy&#8217; From Trump&#8217;s Trade Moves May End Prolonged Economic Slump</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Government

Economics

Federal Reserve

General

ARBB

DELLL

ERIC

US Stock Futures Waver After Two-Day Rally: Trump's Tariff Moves Could End A 3-Year 'Rolling Recession,' Says Expert

Shares of Telefonaktiebolaget LM Ericsson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIC#NASDAQ">ERIC</a>) rose sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ERIC/earnings">first-quarter results.</a>
Ericsson reported that its first-quarter adjusted operating earnings, excluding restructuring charges, jumped 44% year-over-year to 6.2 billion Swedish crowns ($636 million). Its net sales rose 3% year-over-year to 55 billion crowns during the quarter.
Ericsson shares jumped 6.9% to $7.96 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Splash Beverage Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NYSE">SBEV</a>) rose 99.2% to $2.75 in pre-market trading after declining around 4% on Monday.</li>
<li>Synergy CHC Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNYR#NASDAQ">SNYR</a>) surged 55.3% to $2.78 in pre-market trading.</li>
<li>ARB IOT Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBB#NASDAQ">ARBB</a>) gained 42.5% to $0.9120 in pre-market after the company secured approximately $53.0 million order for supplying AI servers.</li>
<li>SUNation Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) rose 17.8% to $0.0338 in pre-market trading after jumping around 28% on Monday.</li>
<li>CISO Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) jumped 17.2% to $0.4699 in pre-market trading after jumping 19% on Monday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) surged 16.6% to $13.70 in pre-market trading after gaining 41% on Monday.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) rose 14% to $7.10 in pre-market trading.</li>
<li>LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) gained 10.7% to $8.50 in pre-market trading.</li>
<li>Gamehaus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMHS#NASDAQ">GMHS</a>) gained 9.5% to $1.46 in pre-market trading after gaining 23% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>DiaMedica Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) fell 52% to $1.70 in pre-market trading.</li>
<li>Unifi, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) shares tumbled 37.6% to $3.01 in pre-market trading after gaining around 4% on Monday.</li>
<li>GeoVax Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) fell 34.6% to $1.55 in pre-market trading after the company announced it received a notification from Advanced Technology International to stop all work on its efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; &#8220;NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine&#8221;</li>
<li>United Security Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBFO#NASDAQ">UBFO</a>) shares fell 34.1% to $5.00 in pre-market trading.</li>
<li>NAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) shares fell 24.7% to $1.70 in pre-market trading. NAYA Biosciences is rebranding as INVO Fertility, and separating fertility and oncology divisions into distinct public and private entities.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) fell 12.3% to $3.11 in today's pre-market trading.</li>
<li>Allegro MicroSystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) fell 12.3% to $19.29 in pre-market trading after ON Semiconductor withdrew its acquisition proposal.</li>
<li>Arlo Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) shares dipped 11.7% to $8.01 in pre-market trading. Arlo Technologies will hold a conference call on Thursday, May 8 to discuss the Company&#8217;s first quarter results.</li>
<li>IRSA Inversiones y Representaciones Sociedad Anónima (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRS#NYSE">IRS</a>) dipped 11.2% to $12.32 in pre-market trading after gaining around 9% on Monday.</li>
<li>Applied Digital Corporation  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) declined 10.8% to $4.79 in pre-market trading following weak quarterly revenue.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44787747/wall-streets-most-accurate-analysts-spotlight-on-3-consumer-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Consumer Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

ALGM

ARLO

CISO

DMAC

GMHS

LION

NAYA

SBEV

SUNE

UBFO

USAR

Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) stock rose 21.4% to $4.7 during Monday's after-market session. The company's market cap stands at $35.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock increased by 15.01% to $0.25. The market value of their outstanding shares is at $11.0 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) shares rose 9.52% to $0.69. The company's market cap stands at $16.4 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares moved upwards by 8.26% to $4.06. The market value of their outstanding shares is at $2.6 million. </li>
<li>BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) shares moved upwards by 7.83% to $0.34. The company's market cap stands at $19.8 million. </li>
<li>NanoVibronix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) stock increased by 7.61% to $8.34. The market value of their outstanding shares is at $6.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares decreased by 29.9% to $0.75 during Monday's after-market session. The market value of their outstanding shares is at $7.0 million. </li>
<li>Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) stock fell 16.07% to $141.77. The company's market cap stands at $4.0 billion. </li>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock declined by 13.67% to $0.56. The company's market cap stands at $98.4 million. </li>
<li>Minerva Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NERV#NASDAQ">NERV</a>) stock declined by 12.11% to $1.38. The market value of their outstanding shares is at $9.6 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock decreased by 10.42% to $0.21. The company's market cap stands at $1.3 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock decreased by 9.31% to $1.17. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCAB

BSGM

CRIS

HCTI

KRYS

MCRB

NAOV

NERV

POCI

VERO

YCBD

12 Health Care Stocks Moving In Monday's After-Market Session

GeoVax Labs shares are trading lower after the company announced it received a notification from Advanced Technology International to stop all work on its efforts with respect to Project Agreement No. 01; RRPV-24-04-NGVx-006; "NextGen Vaccinations: Phase 2B Clinical Trial Execution: Phase 2b study to evaluate GEO-CM04S1 COVID-19 vaccine"

GeoVax Directed By Advanced Technology International To Halt Work On Their Phase 2b Clinical Trial For The GEO-CM04S1 COVID-19 Vaccine, As Part Of A Project Funded By U.S. Department Of Health's BARDA Program.

D. Boral Capital analyst Jason Kolbert maintains Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) with a Buy and maintains $18 price target.

D. Boral Capital Maintains Buy on Geovax Labs, Maintains $18 Price Target

<h3>Companies Reporting Before The Bell</h3>
• Tsakos Energy Navigation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. 
• Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) is projected to report quarterly loss at $1.40 per share on revenue of $2.90 million. 
• PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is projected to report earnings for its fourth quarter. 
• FitLife Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTLF#NASDAQ">FTLF</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $14.95 million. 
• ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) is expected to report quarterly loss at $0.35 per share on revenue of $19.67 million. 
• Telesat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSAT#NASDAQ">TSAT</a>) is expected to report earnings for its fourth quarter. 
• Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is expected to report earnings for its fourth quarter. 
• Bitfarms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BITF#NASDAQ">BITF</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $53.82 million. 
• Winnebago Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WGO#NYSE">WGO</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $608.95 million. 
• BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is estimated to report quarterly earnings at $0.35 per share on revenue of $16.80 million. 
• Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $20.83 million. 
• TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $8.24 million. 
• BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) is likely to report quarterly loss at $0.35 per share on revenue of $2.29 million. 
• Icecure Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCM#NASDAQ">ICCM</a>) is expected to report quarterly loss at $0.07 per share on revenue of $1.07 million. 
• Jiayin Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFIN#NASDAQ">JFIN</a>) is likely to report earnings for its fourth quarter. 
• Ascentage Pharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPG#NASDAQ">AAPG</a>) is projected to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONEK#NASDAQ">UONEK</a>) is estimated to report earnings for its fourth quarter. 
• Urban One (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UONE#NASDAQ">UONE</a>) is projected to report earnings for its fourth quarter. 
• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.91 per share on revenue of $14.79 billion. 
• Sachem Cap (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SACH#AMEX">SACH</a>) is projected to report quarterly loss at $0.46 per share on revenue of $14.49 million. 
• Ermenegildo Zegna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZGN#NYSE">ZGN</a>) is likely to report earnings for its Fiscal Year 2024. 
• Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) is projected to report earnings for its Fiscal Year 2024. 
<h3>Companies Reporting After The Bell</h3>
• Dolphin Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLPN#NASDAQ">DLPN</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $13.52 million. 
• Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) is projected to report earnings for its fourth quarter. 
• Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is projected to report quarterly loss at $0.66 per share on revenue of $1.45 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is projected to report quarterly loss at $0.09 per share on revenue of $3.85 million. 
• SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) is likely to report earnings for its fourth quarter. 
• INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) is projected to report earnings for its fourth quarter. 
• TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) is estimated to report earnings for its fourth quarter. 
• Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is expected to report quarterly loss at $0.40 per share on revenue of $9.03 million. 
• IZEA Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IZEA#NASDAQ">IZEA</a>) is expected to report quarterly loss at $0.08 per share on revenue of $13.00 million. 
• Yxt.Com Group Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YXT#NASDAQ">YXT</a>) is expected to report earnings for its fourth quarter. 
• TSS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>) is expected to report earnings for its fourth quarter. 
• BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) is likely to report quarterly loss at $0.27 per share on revenue of $475 thousand. 
• Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly loss at $0.67 per share on revenue of $12.31 million. 
• Faraday Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) is expected to report earnings for its fourth quarter. 
• 374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) is likely to report quarterly loss at $0.02 per share on revenue of $100 thousand. 
• Lantern Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>) is estimated to report earnings for its fourth quarter. 
• Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) is projected to report quarterly loss at $0.95 per share on revenue of $920 thousand. 
• Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) is likely to report earnings for its fourth quarter. 
• BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter. 
• Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $0.51 per share on revenue of $1.19 million. 
• VirTra (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $8.09 million. 
• Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.37 million. 
• Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) is likely to report quarterly loss at $0.31 per share on revenue of $6.20 million. 
• Beachbody Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) is likely to report quarterly loss at $1.52 per share on revenue of $81.71 million. 
• Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) is expected to report earnings for its fourth quarter. 
• Valhi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHI#NYSE">VHI</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $19.48 million. 
• Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $81.13 million. 
• Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is projected to report quarterly loss at $0.05 per share on revenue of $12.80 million. 
• AAR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>) is projected to report quarterly earnings at $0.96 per share on revenue of $679.95 million. 
• Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) is expected to report quarterly earnings at $1.28 per share on revenue of $383.94 million. 
• P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) is expected to report quarterly loss at $0.17 per share on revenue of $385.80 million. 
• Co-Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) is likely to report quarterly loss at $0.34 per share on revenue of $375 thousand. 
• Argan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) is estimated to report quarterly earnings at $1.11 per share on revenue of $212.05 million. 
• HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) is likely to report quarterly earnings at $0.19 per share on revenue of $9.30 million. 
• Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) is expected to report quarterly earnings at $5.65 per share on revenue of $3.52 billion. 
• Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) is likely to report quarterly loss at $0.11 per share on revenue of $294 thousand. 
• KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $2.87 million. 
• Blaize Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZAI#NASDAQ">BZAI</a>) is expected to report earnings for its fourth quarter. 
• Sky Harbour Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) is expected to report quarterly loss at $0.06 per share on revenue of $4.15 million. 
• Better Choice Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTTR#AMEX">BTTR</a>) is likely to report earnings for its fourth quarter. 
• Pulse Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>) is likely to report earnings for its fourth quarter. 
• Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $155.25 million. 
• Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) is likely to report quarterly loss at $0.14 per share on revenue of $68.43 million. 
• Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is expected to report quarterly loss at $0.14 per share on revenue of $6.83 million. 
• Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) is expected to report quarterly loss at $0.01 per share on revenue of $4.17 million. 
• Abacus Global Management (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) is expected to report quarterly earnings at $0.14 per share on revenue of $30.18 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Geovax Labs

매도 수량

Geovax Labs (NASDAQ:GOVX) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌